Table 5

Prognostic factors affecting overall survival for 79 cases with IVLBCL diagnosed in vivo

VariableUnfavorable factorUnivariate
Multivariate; final model
Hazard ratio (95% CI)PHazard ratio (95% CI)P
CD5 Positive 1.188 (0.661-2.134) .567 ND ND 
PS 2-4 1.472 (0.685-3.163) .321 ND ND 
Extranodal > 1 site 1.535 (0.821-2.871) .18 ND ND 
Serum LDH level High† 3.923 (0.540-28.508) .177 ND ND 
Stage III/IV 4.247 (1.026-17.573) .046 — — 
TCs in BM/PB Yes 2.369 (1.046-5.365) .039 — — 
sIL-2R ≥ 5 × 103 U/mL 2.458 (1.206-5.010) .013 — — 
Platelet < 100 × 109/L 2.375 (1.216-4.639) .011 2.427 (1.217-4.840) .012 
Age > 60 y 2.471 (1.256-4.859) .009 2.459 (1.219-4.960) .012 
Chemotherapy* No 6.413 (2.818-14.594) < .001 9.256 (3.711-23.089) < .001 
VariableUnfavorable factorUnivariate
Multivariate; final model
Hazard ratio (95% CI)PHazard ratio (95% CI)P
CD5 Positive 1.188 (0.661-2.134) .567 ND ND 
PS 2-4 1.472 (0.685-3.163) .321 ND ND 
Extranodal > 1 site 1.535 (0.821-2.871) .18 ND ND 
Serum LDH level High† 3.923 (0.540-28.508) .177 ND ND 
Stage III/IV 4.247 (1.026-17.573) .046 — — 
TCs in BM/PB Yes 2.369 (1.046-5.365) .039 — — 
sIL-2R ≥ 5 × 103 U/mL 2.458 (1.206-5.010) .013 — — 
Platelet < 100 × 109/L 2.375 (1.216-4.639) .011 2.427 (1.217-4.840) .012 
Age > 60 y 2.471 (1.256-4.859) .009 2.459 (1.219-4.960) .012 
Chemotherapy* No 6.413 (2.818-14.594) < .001 9.256 (3.711-23.089) < .001 

TCs in BM/PB indicates tumor cells in the bone marrow or peripheral blood or both; ND, not done; —, not applicable.

*

Anthracycline-based chemotherapy.

†

Higher than the upper limit of the standard range defined by each institution.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal